Daewoong Pharmaceutical launched Nabota, a botulinum toxin-type formula, developed through the drugmaker’s local technology.
According to Dr. Kim Bum-joon, who supervised the clinical trials, Nabota was effective with moderate to severe glabellar lines and showed no significant difference in terms of safety and efficacy when compared with its competitors.
Daewoong said Nabota is already scheduled to be exported to the U.S., Europe, the Middle East and South America.
